US › Healthcare

Bolt Biotherapeutics (BOLT)

US · Healthcare · Biotechnology

$4.00-5.66%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$5,000

Revenue YoY

-99.7%

Net profit

$-7.7M

EPS

$-4.57

EPS estimate

$-2.97

Net margin

-154,400.0%

EPS came in at -4.57 against a street estimate of -2.97 — a miss of 53.9%.

Key statistics

Market cap

$8.3M

Forward P/E

0.0

P/B

0.56

Book value

$6.56

EPS (TTM)

$-16.51

52-week high

$7.20

52-week low

$3.10

50-day MA

$3.71

200-day MA

$4.55

Beta

1.01

Analyst view

Analysts rate Bolt Biotherapeutics a buy (2 buy, 2 hold, 0 sell out of 4) with an average price target of $29.00.

Shareholding

Insiders

3.46%

Institutions

27.92%

Largest institutional holders

Fund	Stake
Sofinnova Ventures	7.15%
Renaissance Technologies Corp	5.12%
Vivo Capital, LLC	3.76%
Citadel Advisors Llc	2.95%
T3 Companies, LLC	1.97%
Board of Ttees Leland Stanford Jr Univ	1.87%
Pfizer Inc	1.63%
Lynx1 Capital Management, LP	1.60%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bolt Biotherapeutics — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.